Vident Advisory LLC Grows Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• Vident Advisory LLC increased its stake in Zimmer Biomet Holdings by 101.6%, owning 14,088 shares valued at approximately $1,595,000 as of the latest SEC filing.
• Zimmer Biomet's stock has seen varying analyst ratings, with a consensus price target of $111.44, and both Stifel Nicolaus and UBS Group recently set different price objectives.
• The company announced a quarterly dividend of $0.24, marking a 0.9% dividend yield, with the ex-dividend date set for September 30th.

Vident Advisory LLC raised its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 101.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 14,088 shares of the medical equipment provider's stock after buying an additional 7,099 shares during the period. Vident Advisory LLC's holdings in Zimmer Biomet were worth $1,595,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Ameriprise Financial Inc. raised its holdings in shares of Zimmer Biomet by 236.0% in the first quarter. Ameriprise Financial Inc. now owns 4,568,287 shares of the medical equipment provider's stock valued at $517,039,000 after purchasing an additional 3,208,596 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Zimmer Biomet by 251.3% in the first quarter. JPMorgan Chase & Co. now owns 2,081,381 shares of the medical equipment provider's stock valued at $235,571,000 after purchasing an additional 1,488,918 shares during the last quarter. Nuveen LLC purchased a new stake in shares of Zimmer Biomet in the first quarter valued at about $155,891,000. Nuveen Asset Management LLC increased its holdings in Zimmer Biomet by 191.8% during the fourth quarter. Nuveen Asset Management LLC now owns 1,389,405 shares of the medical equipment provider's stock worth $146,763,000 after buying an additional 913,310 shares during the last quarter. Finally, Boston Trust Walden Corp purchased a new position in shares of Zimmer Biomet in the first quarter worth about $54,108,000. 88.89% of the stock is owned by institutional investors.

Insider Transactions at Zimmer Biomet

In other news, insider Sang Yi sold 1,000 shares of the company's stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $95.00, for a total transaction of $95,000.00. Following the completion of the sale, the insider owned 20,424 shares of the company's stock, valued at $1,940,280. This represents a 4.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.39% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research firms have issued reports on ZBH. Canaccord Genuity Group lowered their target price on shares of Zimmer Biomet from $115.00 to $101.00 and set a "hold" rating on the stock in a research note on Monday, May 12th. Roth Capital reaffirmed a "buy" rating on shares of Zimmer Biomet in a research note on Thursday, August 7th. Royal Bank Of Canada boosted their price objective on shares of Zimmer Biomet from $112.00 to $115.00 and gave the company an "outperform" rating in a research report on Friday, August 8th. UBS Group boosted their target price on shares of Zimmer Biomet from $91.00 to $96.00 and gave the company a "sell" rating in a report on Friday, August 8th. Finally, Raymond James Financial boosted their target price on shares of Zimmer Biomet from $104.00 to $113.00 and gave the company an "outperform" rating in a report on Friday, August 8th. Nine investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $111.00.

Zimmer Biomet Stock Up 0.8%

Zimmer Biomet stock traded up $0.83 during mid-day trading on Friday, reaching $105.59. The stock had a trading volume of 1,168,434 shares, compared to its average volume of 1,287,856. The company has a market capitalization of $20.92 billion, a price-to-earnings ratio of 25.69, a PEG ratio of 2.08 and a beta of 0.68. The company has a 50-day moving average price of $98.42 and a two-hundred day moving average price of $99.61. Zimmer Biomet Holdings, Inc. has a one year low of $89.22 and a one year high of $114.72. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.98 by $0.09. The company had revenue of $2.08 billion for the quarter, compared to analysts' expectations of $2.06 billion. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. Zimmer Biomet's revenue was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.01 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be paid a $0.24 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.9%. Zimmer Biomet's payout ratio is presently 23.36%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.